Down-regulation of c-Src/EGFR-mediated signaling activation is involved in the honokiol-induced cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells

Cancer Letters

Volumn 277, Issue 2, 2009, Pages 133-140

  Park, Eun Jung ^a   Min, Hye Young ^a   Chung, Hwa Jin ^a   Hong, Ji Young ^a   Kang, You Jin ^a   Hung, Tran Manh ^b   Youn, Ui Joung ^b   Kim, Yeong Shik ^c   Bae, KiHwan ^b   Kang, Sam Sik ^c   Lee, Sang Kook ^a  

^a Ewha Womans University   (South Korea)

^b Chungnam National University   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Apoptosis; Honokiol; MDA MB 231; mTOR; Src

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; HONOKIOL; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; RETINOBLASTOMA PROTEIN; S6 KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FRAGMENTATION; DOWN REGULATION; DRUG STRUCTURE; GENE EXPRESSION; HUMAN; HUMAN CELL; ONCOGENE C MYC; ONCOGENE SRC; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BIPHENYL COMPOUNDS; BREAST NEOPLASMS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DOWN-REGULATION; FEMALE; HUMANS; LIGNANS; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 62749139619     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.11.029     Document Type: Article

References (40)

1. Munroe M.E., Arbiser J.L., and Bishop G.A. Honokiol, a natural plant product, inhibits inflammatory signals and alleviates inflammatory arthritis. J. Immunol. 179 (2007) 753-763
2. Cui H.S., Huang L.S., Sok D.E., Shin J., Kwon B.M., Youn U.J., and Bae K. Protective action of honokiol, administered orally, against oxidative stress in brain of mice challenged with NMDA. Phytomedicine 14 (2007) 696-700
3. Hu H., Zhang X.X., Wang Y.Y., and Chen S.Z. Honokiol inhibits arterial thrombosis through endothelial cell protection and stimulation of prostacyclin. Acta Pharmacol. Sin. 26 (2005) 1063-1068
4. Ho K.Y., Tsai C.C., Chen C.P., Huang J.S., and Lin C.C. Antimicrobial activity of honokiol and magnolol isolated from Magnolia officinalis. Phytother. Res. 15 (2001) 139-141
5. Shigemura K., Arbiser J.L., Sun S.Y., Zayzafoon M., Johnstone P.A., Fujisawa M., Gotoh A., Weksler B., Zhau H.E., and Chung L.W. Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells. Cancer 109 (2007) 1279-1289
6. Bai X., Cerimele F., Ushio-Fukai M., Waqas M., Campbell P.M., Govindarajan B., Der C.J., Battle T., Frank D.A., Ye K., Murad E., Dubiel W., Soff G., and Arbiser J.L. Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J. Biol. Chem. 278 (2003) 35501-35507
7. Nagase H., Ikeda K., and Sakai Y. Inhibitory effect of magnolol and honokiol from Magnolia obovata on human fibrosarcoma HT-1080. Invasiveness in vitro. Planta Med. 67 (2001) 705-708
8. Hirano T., Gotoh M., and Oka K. Natural flavonoids and lignans are potent cytostatic agents against human leukemic HL-60 cells. Life Sci. 55 (1994) 1061-1069
9. Hibasami H., Achiwa Y., Katsuzaki H., Imai K., Yoshioka K., Nakanishi K., Ishii Y., Hasegawa M., and Komiya T. Honokiol induces apoptosis in human lymphoid leukemia Molt 4B cells. Int. J. Mol. Med. 2 (1998) 671-673
10. Yang S.E., Hsieh M.T., Tsai T.H., and Hsu S.L. Down-modulation of Bcl-XL, release of cytochrome c and sequential activation of caspases during honokiol-induced apoptosis in human squamous lung cancer CH27 cells. Biochem. Pharmacol. 63 (2002) 1641-1651
11. Wang T., Chen F., Chen Z., Wu Y.F., Xu X.L., Zheng S., and Hu X. Honokiol induces apoptosis through p53-independent pathway in human colorectal cell line RKO. World J. Gastroenterol. 10 (2004) 2205-2208
12. Battle T.E., Arbiser J., and Frank D.A. The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells. Blood 106 (2005) 690-697
13. Arbiser J., and Anderson K.C. Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. Blood 106 (2005) 1794-1800
14. Sheikh M.S., Garcia M., Pujol P., Fontana J.A., and Rochefort H. Why are estrogen-receptor-negative breast cancers more aggressive than the estrogen-receptor-positive breast cancers?. Invas. Metast. 14 (1994/1995) 329-336
15. Wolf I., O'Kelly J., Wakimoto N., Nguyen A., Amblard F., Karlan B.Y., Arbiser J.L., and Koeffler H.P. Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest. Int. J. Oncol. 30 (2007) 1529-1537
16. Li L., Han W., Gu Y., Qiu S., Lu Q., Jin J., Luo J., and Hu X. Honokiol induces a necrotic cell death through the mitochondrial permeability transition pore. Cancer Res. 67 (2007) 4894-4903
17. Xu D., Lu Q., and Hu X. Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol. Cancer Lett. 243 (2006) 274-280
18. Zandi R., Larsen A.B., Andersen P., Stockhausen M.T., and Poulsen H.S. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal. 19 (2007) 2013-2023
19. Biscardi J.S., Ishizawar R.C., Silva C.M., and Parsons S.J. Tyrosine kinase signaling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res. 2 (2000) 203-210
20. Biscardi J.S., Belsches A.P., and Parsons S.J. Characterization of human epidermal growth factor receptor and c-Src interactions in human breast tumor cells. Mol. Carcinog. 21 (1998) 261-272
21. Nicholson R.I., Gee J.M.W., and Harper M.E. EGFR and cancer prognosis. Eur. J. Cancer 37 (2001) S9-S15
22. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., and Boyd M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82 (1990) 1107-1112
23. 1 cell cycle arrest and apoptosis in human promyelocytic leukemia HL-60 cells. Biochem Pharmacol. 70 (2005) 918-924
24. Lee S.K., Heo Y.H., Steele V.E., and Pezzuto J.M. Induction of apoptosis by 1,4-phenylenebis(methylene)selenocyanate in cultured human colon cancer cells. Anticancer Res. 22 (2002) 97-102
25. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., and Klenk D.C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150 (1985) 76-85
26. Zimmermann K.C., Bonzon C., and Green D.R. The machinery of programmed cell death. Pharmacol. Ther. 92 (2001) 57-70
27. Pelengaris S., Khan M., and Evan G. c-Myc: more than just a matter of life and death. Nat. Rev. Cancer 2 (2002) 764-776
28. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., and Mills G.B. Exploiting the PI3K/Akt pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4 (2005) 988-1004
29. Wullschleger S., Loewith R., and Hall M.N. TOR signaling in growth and metabolism. Cell 124 (2006) 471-484
30. Bagatell R., and Whitesell L. Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol. Cancer Ther. 3 (2004) 1021-1030
31. Mann J. Natural products in cancer chemotherapy: past, present and future. Nat. Rev. Cancer 2 (2002) 143-148
32. Shapiro G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 24 (2006) 1770-1783
33. Kopelovich L., Fay J.R., Sigman C.C., and Crowell J.A. The mammalian target of rapamycin pathway as a potential target for cancer chemoprevention. Cancer Epidermiol. Biomarkers Prev. 16 (2007) 1330-1340
34. Garcia A., Zheng Y., Zhao C., Toschi A., Fan J., Shraibman N., Brown H.A., Bar-Sagi D., Foster D.A., and Arbiser J.L. Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells. Clin. Cancer Res. 14 (2008) 4267-4274
35. Raja S.M., Chen S., Yue P., Acker T.M., Lefkove B., Arbiser J.L., Khuri F.R., and Sun S.Y. The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor-induced apoptosis. Mol. Cancer Ther. 7 (2008) 2212-2223
36. Lin S.Y., Chang Y.T., Liu J.D., Yu C.H., Ho Y.S., Lee Y.H., and Lee W.S. Molecular mechanisms of apoptosis induced by magnolol in colon and liver cancer cells. Mol. Carcinogen. 32 (2001) 73-83
37. Yang S.E., Hsieh M.T., Tsai T.H., and Hsu S.L. Effector mechanism of magnolol-induced apoptosis in human lung squamous carcinoma CH27 cells. Br. J. Pharmacol. 138 (2003) 193-201
38. Huang S.H., Chen Y., Tung P.Y., Wu J.C., Chen K.H., Wu J.M., and Wang S.M. Mechanisms for the magnolol-induced cell death of CGTH W-2 thyroid carcinoma cells. J. Cell. Biochem. 101 (2007) 1011-1022
39. Li H.B., Yi X., Gao J.M., Ying X.X., Guan H.Q., and Li J.C. Magnolol-induced H460 cells death via autophagy but not apoptosis. Arch. Pharm. Res. 30 (2007) 1566-1574
40. Lee S.Y., Yuk D.Y., Song H.S., Yoon D.Y., Jung J.K., Moon D.C., Lee B.S., and Hong J.T. Growth inhibitory effects of obovatol through induction of apoptotic cell death in prostate and colon cancer by blocking of NF-kappaB. Eur. J. Pharmacol. 582 (2008) 17-25